MiNK Therapeutics, Inc. Accumulated Other Comprehensive Income
MiNK Therapeutics, Inc. (INKT) had Accumulated Other Comprehensive Income of -$699.89 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-13
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$699.89K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$697.43K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$718.92K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$692.11K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$699.89K 10-Q · filed 2026-08-13 |
| 2026-03-31 | -$697.43K 10-Q · filed 2026-05-15 |
| 2025-12-31 | -$718.92K 10-Q · filed 2026-08-13 |
| 2025-09-30 | -$692.11K 10-Q · filed 2025-11-14 |
| 2025-06-30 | -$719.32K 10-Q · filed 2025-08-14 |
| 2025-03-31 | -$662.44K 10-Q · filed 2025-05-15 |
| 2024-12-31 | -$631.58K 10-K · filed 2026-03-31 |
| 2024-09-30 | -$672.84K 10-Q · filed 2024-11-14 |
| 2024-06-30 | -$611.38K 10-Q · filed 2024-08-13 |
| 2024-03-31 | -$385.78K 10-Q · filed 2024-05-14 |
| 2023-12-31 | -$430.95K 10-K · filed 2025-03-18 |
| 2023-09-30 | -$313.19K 10-Q · filed 2023-11-14 |
| 2023-06-30 | -$401.81K 10-Q · filed 2023-08-10 |
| 2023-03-31 | -$373.80K 10-Q · filed 2023-05-11 |
| 2022-12-31 | -$292.47K 10-K · filed 2024-03-21 |
| 2022-09-30 | -$78.28K 10-Q · filed 2022-11-03 |
| 2022-06-30 | $1.30M 10-Q · filed 2022-08-15 |
| 2022-03-31 | -$102.50K 10-Q · filed 2022-05-13 |
| 2021-12-31 | -$625.27K 10-K · filed 2023-03-24 |
| 2021-09-30 | -$789.34K 10-Q · filed 2021-11-29 |
| 2020-12-31 | -$1.52M 10-K · filed 2022-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |